Zimmer Biomet Holdings Inc. ($ZBH) Stock Forecast: Up 5.3% Today

What is Zimmer Biomet Holdings Inc.?

Zimmer Biomet Holdings Inc. (ZBH) is a prominent player in musculoskeletal healthcare, known for its innovative solutions in orthopedic procedures and robotics. The company's stock had a strong bullish movement today, outperforming competitors and marking its sixth consecutive day of gains.

Why is Zimmer Biomet Holdings Inc. going up?

ZBH stock is up 5.3% on Apr 14, 2026 14:26

• The bullish movement in ZBH stock can be attributed to positive analyst coverage and market sentiment surrounding the company's resilience in navigating supply chain challenges in the medtech industry.
• Analysts' cautiously optimistic views, particularly from Leerink Partners initiating coverage with a Market Perform rating and a price target of $101.00, have likely bolstered investor confidence in Zimmer Biomet's long-term growth prospects.
• The company's recent surpassing of Q4 earnings expectations and strategic restructuring, including the launch of new products like the mBôs robot, have also contributed to the positive momentum in its stock price.
• Despite potential near-term growth limitations due to market dynamics, ZBH's strong balance sheet, leadership in robotics, and focus on addressing supply chain disruptions position it favorably for sustained gains in the future.

ZBH Price Chart

ZBH Technical Analysis

ZBH News

Zimmer Biomet stock (US98956P1021): Is supply chain resilience now the real test for medtech growth?

Zimmer Biomet Holdings, a leader in musculoskeletal healthcare, faces increasing scrutiny regarding supply chain resilience amidst a push for stronger industrial supply chains in the U.S. The company's ability to navigate these pressures and technological shifts will be crucial for its future growth, despite strong demand driven by aging populations and orthopedic procedure growth. Analysts maintain a cautiously optimistic view, with the company's strong balance sheet and leadership in areas like robotics positioning it for long-term gains, while highlighting risks such as supply chain disruptions and competitive dynamics.

https://www.ad-hoc-news.de/boerse/ueberblick/zimmer-biomet-stock-us98956p1021-is-supply-chain-resilience-now-the/69140418

Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day

Shares of Zimmer Biomet Holdings Inc. (ZBH) rose 2.38% to $95.34 on Monday, outperforming the broader market. This marked the stock's sixth consecutive day of gains, occurring on a strong trading day where the S&P 500 Index and Dow Jones Industrial Average also saw increases.

https://www.marketwatch.com/data-news/zimmer-biomet-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-907b88d5-dfc2eae39e7b

Leerink initiates Zimmer Biomet stock coverage with Market Perform By Investing.com

Leerink Partners initiated coverage on Zimmer Biomet Holdings Inc. (NYSE:ZBH) with a Market Perform rating and a price target of $101.00, citing that the company trades at a discount to peers. While near-term growth is sensitive to market share shifts and pricing, Leerink sees potential upside in 2027 and beyond from new product launches, including semi-autonomous and fully-autonomous mBôs robots. Other analyst firms have offered varied perspectives, with Argus reiterating a Buy rating and BTIG downgrading to Neutral due to differing views on growth prospects.

https://m.in.investing.com/news/stock-market-news/leerink-initiates-zimmer-biomet-stock-coverage-with-market-perform-93CH-5334492?ampMode=1

Leerink initiates Zimmer Biomet stock coverage with Market Perform By Investing.com

Leerink Partners initiated coverage on Zimmer Biomet Holdings Inc. (NYSE:ZBH) with a Market Perform rating and a price target of $101.00. While the stock appears undervalued according to InvestingPro analysis, Leerink notes that near-term growth is sensitive to market share shifts and pricing, but potential upside exists in 2027 and beyond from new product launches. The company has recently surpassed Q4 earnings expectations and is restructuring its US sales force, though analysts have varied outlooks.

https://ca.investing.com/news/stock-market-news/leerink-initiates-zimmer-biomet-stock-coverage-with-market-perform-93CH-4561444

Leerink initiates Zimmer Biomet stock coverage with Market Perform

Leerink Partners initiated coverage on Zimmer Biomet Holdings Inc. (NYSE:ZBH) with a Market Perform rating and a price target of $101.00, citing its discount to peers and alignment with consensus revenue and EPS estimates for 2026. The firm highlighted potential upside in 2027 and beyond from new product launches like the mBôs robot, but noted near-term growth could be limited by market share shifts and pricing. Other analysts, including Argus and William Blair, have offered varied perspectives on the company's future after recent earnings and strategic restructuring.

https://m.investing.com/news/analyst-ratings/leerink-initiates-zimmer-biomet-stock-coverage-with-market-perform-93CH-4610282?ampMode=1

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.0% Today

Instacart (Maplebear Inc) ($CART) Stock Forecast: Up 5.4% Today

Credo Technology Group ($CRDO) Stock Forecast: Up 5.4% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Up 5.2% Today

Power Integrations Inc. ($POWI) Stock Forecast: Up 5.3% Today

Whirlpool Corporation ($WHR) Stock Forecast: Up 5.1% Today

Sirius XM Holdings Inc. ($SIRI) Stock Forecast: Up 5.0% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Up 6.5% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 5.1% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 14.0% Today

Zimmer Biomet Holdings Inc. Price History

13.00.2026 - ZBH Stock was down 2.3%

• During the third quarter of 2025, Nisa Investment Advisors LLC notably decreased its ownership in Zimmer Biomet Holdings, Inc. by 39.8%, potentially indicating a lack of faith in the company's upcoming performance, which might have contributed to the recent market decline.
• Zimmer Biomet Holdings Inc. demonstrated weaker performance compared to its industry counterparts, potentially due to factors beyond what has been publicly revealed, fostering a pessimistic market mood.
• The departure of Mark Bezjak, a vital executive at Zimmer Biomet Holdings, triggered concerns among shareholders regarding leadership stability and future strategic plans, adversely affecting the stock value.
• Following Mark R. Bezjak's appointment at Dentsply Sirona, where he previously held leadership positions at Zimmer Biomet, investors may have grown uneasy about potential competitive shifts towards a rival firm, leading to the downturn in Zimmer Biomet's stock price.

10.01.2026 - ZBH Stock was up 5.3%

• Strong fourth-quarter financial results from Zimmer Biomet exceeded revenue and earnings predictions, leading to the stock's upward trend.
• Despite the positive results, the company's cautious approach to its 2026 guidance, citing the ever-changing healthcare landscape, initially caused a slight decline in pre-market stock prices.
• The strategic shift towards a direct and specialized sales model in the U.S., as highlighted by the CEO, likely bolstered investor confidence in the company's future growth.
• A newly announced $1.5 billion stock repurchase program also contributed to positive investor sentiment and the stock's upward trajectory.

09.03.2025 - ZBH Stock was down 5.1%

• Despite Zimmer Biomet's strategic global expansion efforts and focus on volume growth, the stock faced a bearish movement.
• Rising costs may have outweighed the positive impact of increased demand in the musculoskeletal space.
• Investors might be concerned about the company's ability to effectively manage and control its escalating costs, leading to the downward pressure on the stock price.
• The market sentiment towards the healthcare sector or broader economic factors could also have contributed to the bearish movement in ZBH stock today.

14.00.2026 - ZBH Stock was down 5.2%

• ZBH shares exhibited a significant drop following the company's conservative statements about its future at the J.P. Morgan Healthcare Conference, reflecting concerns among investors about its upcoming performance.
• Despite the recent bearish market movement, evaluations still consider Zimmer Biomet a worthwhile investment opportunity, supported by favorable valuation metrics and financial stability. This indicates that short-term apprehensions may be overshadowing its long-term prospects.
• The decision from Nisa Investment Advisors LLC to sell ZBH shares, alongside other institutional investors increasing their holdings, could have amplified the selling pressure, contributing to the downward trend.
• The recent appointment of Mark R. Bezjak as Group Vice President at Dentsply Sirona, who had a prior role at Zimmer Biomet, might have indirectly influenced the market sentiment towards ZBH, prompting investors to evaluate potential implications on competitiveness and industry dynamics.

07.07.2025 - ZBH Stock was up 9.5%

• The market reacted positively to the upcoming Q2 earnings report for ZBH, with expectations of strength in Hips, Knees, and S.E.T. segments.
• Despite a projected year-over-year earnings dip, investors seem optimistic about the company's performance in key areas.
• This positive outlook could be driving the bullish movement in ZBH's stock price today, as investors anticipate resilience and growth in critical product lines.

07.07.2025 - ZBH Stock was up 7.5%

• ZBH stock saw a strong bullish trend today due to the release of their Q2 earnings and revenue beating expectations, along with an increase in full-year EPS guidance. This positive development suggests promising performance and growth potential for the company.
• Investors reacted positively to ZBH's robust showing in the Hips, Knees, and S.E.T. segments, despite an anticipated decline in year-over-year earnings. The focus appears to be on the overall positive outcomes and updated guidance.
• The market's reaction may also be attributed to ZBH's adept navigation of the competitive medical device industry landscape and its consistent delivery of strong financial results, which has bolstered investor confidence.

04.01.2026 - ZBH Stock was up 2.8%

• ZBH stock experienced a strong bullish movement recently.
• Positive market sentiment was fueled by expectations of increased earnings and higher revenues for the quarter ending December 2025.
• Despite some analyst revisions and a negative Earnings ESP, optimistic growth projections and the company's robust fundamentals likely boosted investor confidence.
• The increase in stake by the National Pension Service and the company's solid reputation as a reliable dividend cornerstone might have positively impacted the stock's performance.

14.03.2026 - ZBH Stock was up 5.3%

• The bullish movement in ZBH stock can be attributed to positive analyst coverage and market sentiment surrounding the company's resilience in navigating supply chain challenges in the medtech industry.
• Analysts' cautiously optimistic views, particularly from Leerink Partners initiating coverage with a Market Perform rating and a price target of $101.00, have likely bolstered investor confidence in Zimmer Biomet's long-term growth prospects.
• The company's recent surpassing of Q4 earnings expectations and strategic restructuring, including the launch of new products like the mBôs robot, have also contributed to the positive momentum in its stock price.
• Despite potential near-term growth limitations due to market dynamics, ZBH's strong balance sheet, leadership in robotics, and focus on addressing supply chain disruptions position it favorably for sustained gains in the future.

05.10.2025 - ZBH Stock was down 12.5%

• Weak performance in Latin America and specific EU markets affected the projected organic growth, resulting in a decline in the stock value.
• Despite the positive earnings, the stock has been on a downward trajectory in the past year, potentially contributing to the recent bearish trend.
• An uptick in short interest as a percentage of float suggests a growing bearish outlook among investors, adding to the downward pressure on the stock.
• Market sentiment towards Zimmer Biomet Holdings Inc. appears cautious, with investors closely monitoring its performance in key markets.

05.10.2025 - ZBH Stock was down 10.2%

• The decrease in Zimmer Biomet Holdings Inc.'s stock price today could be attributed to the negative trend in its P/E ratio, indicating potential overvaluation concerns among investors.
• The rise in short interest percentage suggests that more investors are betting against the company, possibly due to concerns about its future performance or market conditions.
• These factors combined may have led to a lack of confidence in Zimmer Biomet Holdings Inc.'s stock, resulting in the bearish movement observed today.

05.10.2025 - ZBH Stock was down 15.5%

• Despite Zimmer Biomet exceeding Q3 earnings forecasts, the stock faced a decline in revenue and a reduced outlook, resulting in an early slide.
• Challenges in Latin America and select EU markets affected the company's projected organic growth, contributing to the stock's downward trend.
• The stock price dropped by 0.84% in the latest market session, marking a significant 9.34% decrease over the past year.
• Zimmer Biomet Holdings Inc.'s short interest as a percentage of float has increased, indicating a rise in bearish sentiment among investors.

05.04.2025 - ZBH Stock was down 5.3%

• Zimmer Biomet showed robust earnings in the first quarter, signaling a favorable beginning to the year.
• Despite surpassing earnings expectations, the stock saw a bearish trend following a decrease in the operating margin, sparking concerns among stakeholders regarding profitability.
• The market's response to the decline in operating margin suggests that investors are highly attuned to any indications of financial uncertainties for the company.